Lung cancer trials in United States

In United States 901 Also abroad 2733

901 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Detection of Genetic Markers of Lung Cancer
Where
Pittsburgh
Age
18 years and over
People
6,000
Run by
University of Pittsburgh
See details and how to joinNCT00280202
Phase 1Taking people
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Where
Houston
Age
12 years to 50 years
People
44
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT03093909
Phase 4Taking people
Dabrafenib and/or Trametinib Rollover Study
Where
Bethesda, Columbus, Dallas, Scottsdale
Age
18 years to 100 years
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
Phase 2Taking people
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Where
Boston, Grand Rapids, Houston, Los Angeles, Nashville, New Haven, Newton, Trumbull
Age
18 years and over
People
430 worldwide
Run by
Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00
Phase 1Taking people
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Where
Bethesda
Age
18 years to 120 years
People
30
Run by
National Cancer Institute (NCI)
See details and how to joinNCT06066138
Phase 3Taking people
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Where
Annapolis, Auburn, Barrington, Birmingham, Cary, Dallas, Edinburg, Elmhurst, Fort Wayne, Fullerton, Gig Harbor, Goodyear, Houston, Indianapolis, Jacksonville, Kansas City, Lee's Summit, Naperville, New Hyde Park, Newport Beach, New York, Ocala, Overland, Philadelphia, Pittsburgh, Puyallup, Richardson, Rochester, Sacramento, San Antonio, Shirley, Spokane, Tacoma, Tampa, The Bronx, Westwood, Zion
Age
18 years and over
People
734 worldwide
Run by
NovoCure GmbH
See details and how to joinNCT06216301
Phase 3Taking people
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Where
Albany, Atlanta, Baton Rouge, Beverly Hills, Bluffton, Charleston, Columbus, Edgewood, Elmhurst, Evanston, Fargo, Fort Wayne, Hershey, Houston, Ithaca, Jacksonville, Knoxville, Lafayette, Lancaster, Lisle, Little Rock, Los Angeles, Miami Beach, Minneapolis, Morristown, Naperville, Newnan, Newport Beach, Oklahoma City, Orange, Orange City, Portland, Reno, Rochester, Salt Lake City, San Francisco, Savannah, Sioux Falls, Springdale, Stamford, St Louis, Stony Brook, Thomasville, Westbrook, White Plains
Age
18 years and over
People
780 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00
Phase 3Taking people
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Where
Albany, Bakersfield, Beverly Hills, Billings, Cincinnati, Houston, Kansas City, Kettering, Lancaster, Madison, Miami Beach, Morristown, Skokie, Springfield, Stamford
Age
18 years and over
People
348 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Where
Albuquerque, Austin, Bismarck, Cincinnati, Daphne, Durham, Edmonds, Fargo, Fort Myers, Hot Springs, Marietta, Minneapolis, Nashville, Orange City, Peoria, Roanoke, Seattle, Sioux Falls, St. Petersburg, Tyler
Age
18 years and over
People
530 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00
Phase 2Taking people
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
Where
Austin, Cleveland, Fairfax, Manahawkin, Pittsburgh, Weston
Age
18 years and over
People
40 worldwide
Run by
Wayshine Biopharm, Inc.
See details and how to joinNCT06868485
Phase 1/2Taking people
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Where
Ann Arbor, Baltimore, Boston, Charlottesville, Fairfax, Houston, Los Angeles, Nashville, New York, Philadelphia, Salt Lake City, Seattle, St Louis
Age
18 years and over
People
616 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT07020221
Phase 3Taking people
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Where
Canton, East Syracuse, Fort Worth, Hialeah, Hinsdale, Los Angeles, Miami, Plantation, Tamarac, Wilson
Age
18 years and over
People
420 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07099898
Phase 3Taking people
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Where
Albany, Bend, Beverly Hills, Birmingham, Farmington, Fort Lauderdale, Fredericksburg, Hackensack, Lafayette, Lancaster, Miami Beach, Midlothian, Minneapolis, Morgantown, Roanoke, Rochester, Savannah, Stamford, Westbrook
Age
18 years and over
People
675 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00
Phase 2Taking people
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Where
Clermont, Fargo, Sioux Falls
Age
18 years and over
People
140 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07252739 · EU 2025-521939-36-00
Phase 3Taking people
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Where
Albuquerque, Austin, Baltimore, Boston, Brandywine, Bridgeton, Chandler, Charlottesville, Chicago, Columbia, Denton, Detroit, Duarte, East Syracuse, Eau Claire, Fairfax, Fort Myers, Gilbert, Goodyear, Grand Junction, Greenville, Hershey, Hinsdale, Irvine, Jacksonville, La Jolla, Lancaster, Lincoln, Loma Linda, Los Angeles, Louisville, Marietta, Memphis, Morgantown, Newark, Newnan, Niles, Plano, Portland, Rochester, San Diego, South Portland, St. Petersburg, Tacoma, Tampa, Washington D.C., West Palm Beach, Wheat Ridge, Williamsburg, Zion
Age
18 years and over
People
400 worldwide
Run by
AstraZeneca
See details and how to joinNCT07291037 · EU 2024-520101-39-00
No phaseTaking people
A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients
Where
Winston-Salem
Age
50 years to 77 years
People
27,000
Run by
Wake Forest University Health Sciences
See details and how to joinNCT07322367
Phase 3Taking people
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Where
Ann Arbor, Atlanta, Baltimore, Fayetteville, Hialeah, Kansas City, Little Rock, Louisville, Madison, Memphis, Mobile, Monroe, Omaha, Pikeville, Pittsburgh, Shreveport
Age
18 years and over
People
670 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00
Phase 1Taking people
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Where
Austin, Celebration, Denver, Detroit, Duarte, East Brunswick, Fairfax, Fort Worth, Houston, Irvine, Irving, Lake Success, Nashville, New Haven, New York, Plantation, San Antonio, Sarasota, Spokane, West Valley City
Age
18 years and over
People
150 worldwide
Run by
IDEAYA Biosciences
See details and how to joinNCT07503808 · EU 2026-526299-21-00
Phase 3Taking people
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Where
Albany, Fairfax, Lincoln, Lisle, New Brunswick, Raleigh, Savannah
Age
18 years and over
People
310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00
Phase 3Taking people
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Where
Baltimore, Beaumont, Beverly Hills, Boulder, Charlotte, Chicago, Dallas, Easton, Edina, Fairfax, Fort Myers, Fullerton, La Jolla, Lebanon, Memphis, Morgantown, New Brunswick, New York, Omaha, Orlando, Ottawa, Palm Bay, Portland, Saint Paul, Salt Lake City, San Antonio, Sandusky, Seattle, Silver Spring, Sioux Falls, St Louis, St. Petersburg, The Bronx, Washington D.C., West Palm Beach, Winchester
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680790 · EU 2026-526486-21-00
Phase 2Not yet taking people in United States
Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer
Where
Charleston
Age
18 years to 80 years
People
38
Run by
Medical University of South Carolina
See details and how to joinNCT07720167
Phase 1/2Taking people
A Study of DS-3939a in Participants With Solid Tumors
Where
Fairfax, Fayetteville, Houston, Los Angeles, Portland, Providence, Tampa
Age
18 years and over
People
400 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07739966 · EU 2026-525218-75-00
Phase 2Taking people
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Where
Indianapolis
Age
18 years and over
People
10
Run by
Indiana University
See details and how to joinNCT07761910
Phase 1/2Taking people
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
Where
Boston, East Brunswick, Miami, Nashville, New York
Age
18 years and over
People
55 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07843940 · EU 2026-525459-99-00
Phase 1/2Not yet taking people in United States
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
Where
Bethesda
Age
18 years to 120 years
People
67
Run by
National Cancer Institute (NCI)
See details and how to joinNCT07902921